Studies on immunostimulatory effect of efcovida powder on Cyclophosphamide-induced immunosuppression in mice

To evaluate the immunostimulatory activity of Efcovida powder, we induced immunosuppression in Swiss mice by cyclophosphamide (CP). Efcovida powder at two doses of 60 mg/kg b.w and 120 mg/kg b.w were administered orally for seven consecutive days to animals. CP (200 mg/kg i.p.) was injected on the 4th day. The result showed that Efcovida powder at the dose of 60 mg/kg b.w only posed an immunostimulating potency in the cyclophosphamide-induced immunosuppression model while Efcovida powder at the dose of 120 mg/kg b.w significantly ameliorated the effects of CP on delayed-type hypersensitivity (DTH) response, leukocyte quantity, relative thymus weight, serum IL-4, IL-6 concentration, and micro-histological images of spleen and thymus. This suggested the potential of Efcovida powder to treat immunosuppression diseases in clinical practice.